|
| General Information |
| Business: |
We are a biotherapeutic company focused on developing a cell-based therapy targeting treatment of all forms of acute liver failure. Our product candidate, the ELAD System, is an extracorporeal bio-artificial liver therapy designed to allow the patient’s own liver to regenerate to a healthy state or to stabilize the patient until transplant. The ELAD System is the only bio-artificial liver support system containing immortal human liver-derived cells, or C3A cells, to enter Phase 3 clinical trials. We designed the ELAD System to supplement key aspects of normal liver function to improve patient survival. We are currently conducting two Phase 3 clinical trials and plan to conduct one Phase 2/3 clinical trial. In March 2013, we initiated VTI-208, a Phase 3 randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation, or AILD. In addition, we are conducting a second Phase 3 randomized, controlled clinical trial, VTI-210, in 120 subjects with acute severe alcoholic hepatitis, or AAH, which is a subset of AILD, and expect to initiate the enrollment of subjects in VTI-210 the first half of 2014. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
70 |
Founded: |
2003 |
|
| Contact Information |
| Address: |
15010 Avenue of Science, Suite 200, San Diego, CA 92128, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -39.1 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
VTL |
| Shares (millions): |
4.5 |
| Price Range: |
$12.00 - $12.00 |
| Est.$ Volume |
$ 54.0 mil |
| Manager / Joint Managers |
BofA Merrill Lynch/ Credit Suisse |
| Co Managers |
William Blair/ Canaccord Genuity |
| Expected to Trade |
4/17/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
